Longeveron (LGVN) Short term Debt (2021 - 2023)
Longeveron's (LGVN) quarterly Short term Debt came in at $586000.0 in Q3 2023, up 1.38% quarter-over-quarter from $578000.0 in Q2 2023.
Longeveron (LGVN) Short term Debt (2021 - 2023) Analysis & Trends
Longeveron's Short term Debt history runs 3 years deep, the most recent figure standing at $586000.0 for Q3 2023.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $586000.0 in Q3 2023; TTM through Sep 2023 was $586000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $564000.0, up 5.03% from the prior year.
- Short term Debt advanced to $586000.0 in Q3 2023 per LGVN's latest filing, from $578000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $586000.0 in Q3 2023 and bottomed at $537000.0 in Q4 2021.
- The 3-year median for Short term Debt is $571000.0 (2023), against an average of $567200.0.
- Biggest YoY gain for Short term Debt was 5.03% in 2022; the steepest drop was 5.03% in 2022.
- Year by year, Short term Debt stood at $537000.0 in 2021, then advanced by 5.03% to $564000.0 in 2022, then advanced by 3.9% to $586000.0 in 2023.
- Per Business Quant, the three latest LGVN Short term Debt figures stand at $586000.0 (Q3 2023), $578000.0 (Q2 2023), and $571000.0 (Q1 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 586,000.00 |
| Jun 30, 2023 | 578,000.00 |
| Mar 31, 2023 | 571,000.00 |
| Dec 31, 2022 | 564,000.00 |
| Dec 31, 2021 | 537,000.00 |